Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong
· Delayed Price · Currency is HKD 50.00
-3.10 (-5.84%)
At close: Mar 6, 2026
Xuanzhu Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 31.96 | 30.09 | 0.03 | - | - | - |
| Revenue Growth (YoY) | - | 103672.41% | - | - | - | - |
| Cost of Revenue | 18.4 | 14.94 | 2.19 | - | - | - |
| Gross Profit | 13.56 | 15.16 | -2.17 | - | - | - |
| Selling, General & Admin | 383.04 | 389.51 | 95.69 | 66.4 | 40.64 | 40.83 |
| Research & Development | 195.67 | 186.4 | 239.06 | 350.17 | 197.71 | 308.67 |
| Other Operating Expenses | 2.66 | 2.51 | 2.4 | 0.4 | 0.36 | 1.46 |
| Operating Expenses | 581.37 | 578.42 | 337.14 | 416.96 | 238.69 | 350.99 |
| Operating Income | -567.81 | -563.26 | -339.31 | -416.96 | -238.69 | -350.99 |
| Interest Expense | -0.35 | -0.3 | -1.17 | -1.09 | -0.39 | -19.56 |
| Interest & Investment Income | - | - | - | 31.39 | 8 | 0.54 |
| Currency Exchange Gain (Loss) | 0.08 | - | - | -0.01 | 0.02 | -1.22 |
| Other Non Operating Income (Expenses) | 14.18 | 14.77 | 40.03 | -0.1 | -0.06 | -0.07 |
| EBT Excluding Unusual Items | -553.9 | -548.8 | -300.45 | -386.77 | -231.11 | -371.3 |
| Gain (Loss) on Sale of Investments | -3.35 | -0.02 | -0.01 | 0.11 | 2.53 | - |
| Gain (Loss) on Sale of Assets | 0.94 | -7.56 | - | -0.02 | 56.02 | 0.02 |
| Asset Writedown | -0.05 | -0.05 | -0.1 | -92.25 | - | - |
| Other Unusual Items | - | - | - | 17.36 | 10.12 | 9.57 |
| Pretax Income | -556.36 | -556.42 | -300.56 | -461.58 | -162.45 | -361.71 |
| Income Tax Expense | 0.01 | 0.01 | 0.01 | - | - | - |
| Net Income | -556.36 | -556.43 | -300.56 | -461.58 | -162.45 | -361.71 |
| Net Income to Common | -556.36 | -556.43 | -300.56 | -461.58 | -162.45 | -361.71 |
| Shares Outstanding (Basic) | 451 | 451 | 451 | 395 | - | - |
| Shares Outstanding (Diluted) | 451 | 451 | 451 | 395 | - | - |
| Shares Change (YoY) | 14.22% | - | 14.22% | - | - | - |
| EPS (Basic) | -1.23 | -1.23 | -0.67 | -1.17 | - | - |
| EPS (Diluted) | -1.23 | -1.23 | -0.67 | -1.17 | - | - |
| Free Cash Flow | -197.13 | -127.6 | -117.69 | -487.42 | -264.9 | -485.17 |
| Free Cash Flow Per Share | -0.44 | -0.28 | -0.26 | -1.24 | - | - |
| Gross Margin | 42.43% | 50.37% | - | - | - | - |
| Operating Margin | -1776.79% | -1871.67% | -1170020.69% | - | - | - |
| Profit Margin | -1740.97% | -1848.97% | -1036420.69% | - | - | - |
| Free Cash Flow Margin | -616.87% | -424.00% | -405831.03% | - | - | - |
| EBITDA | -544.87 | -535.73 | -315.26 | -398.82 | -223.22 | -342.34 |
| D&A For EBITDA | 22.94 | 27.53 | 24.04 | 18.14 | 15.47 | 8.65 |
| EBIT | -567.81 | -563.26 | -339.31 | -416.96 | -238.69 | -350.99 |
Source: S&P Capital IQ. Standard template. Financial Sources.